文献速递心脑血管急症重症综合管理与镇静镇痛

肺动脉导管监测在心源性休克中的应用:系统评价与Meta分析

Pulmonary Artery Catheter Monitoring in Cardiogenic Shock: A Systematic Review and Meta-Analysis.
PubMed 文献 · Shock · 2026-01-27
一句话结论系统评价与Meta分析显示,肺动脉导管使用与心源性休克患者住院/30天死亡率降低相关(OR 0.70),同时与机械循环支持启动增加和脓毒症风险增加相关。

该系统评价与Meta分析检索了2015至2025年MEDLINE、Cochrane和Scopus的观察性研究,纳入14项研究共789,553例成人心源性休克患者(271,305例死亡),总体死亡率平均34%。肺动脉导管使用与死亡率降低相关(OR 0.70,95%CI 0.63-0.78,P<0.001),在各心源性休克表型中获益一致,但异质性显著(I²>90%);时间-事件分析(7项研究,n=5,142)证实相对风险比为0.68(95%CI 0.60-0.77,I²=34%)。肺动脉导管使用还与机械循环支持启动增加相关(OR 2.76,95%CI 1.82-4.20,P<0.001),存在发表偏倚(Egger P=0.0057),剪补法校正后OR 3.98;并与脓毒症风险增加相关(OR 1.83,95%CI 1.42-2.35,I²=61%)。作者认为研究结果支持将系统性肺动脉导管使用作为心源性休克的治疗促进手段,并应指导方案制定和未来随机临床试验设计。

要点

  • 成人心源性休克患者中,肺动脉导管使用与住院/30天死亡率降低相关(OR 0.70,95%CI 0.63-0.78,P<0.001),但异质性显著(I²>90%)。
  • 时间-事件分析(7项研究,n=5,142)显示肺动脉导管使用与死亡风险降低32%相关(HR 0.68,95%CI 0.60-0.77,I²=34%)。
  • 肺动脉导管使用与机械循环支持启动增加相关(OR 2.76,95%CI 1.82-4.20,P<0.001),存在发表偏倚(Egger P=0.0057),剪补法校正后OR 3.98。
  • 肺动脉导管使用与脓毒症风险增加相关(OR 1.83,95%CI 1.42-2.35,I²=61%)。
  • 作者认为研究结果支持将系统性肺动脉导管使用作为心源性休克的治疗促进手段,并应指导方案制定和未来随机临床试验设计。

适用人群与场景

  • 成人心源性休克患者,来自观察性研究(2015-2025年)。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入14项观察性研究,共789,553例成人心源性休克患者,271,305例死亡,总体死亡率平均34%。
  • 肺动脉导管使用与住院/30天死亡率降低相关:OR 0.70(95%CI 0.63-0.78,P<0.001),各心源性休克表型获益一致,但异质性显著(I²>90%)。
  • 时间-事件分析(7项研究,n=5,142):HR 0.68(95%CI 0.60-0.77,I²=34%),即相对风险降低32%。
  • 肺动脉导管使用与机械循环支持启动增加相关:OR 2.76(95%CI 1.82-4.20,P<0.001),存在发表偏倚(Egger P=0.0057),剪补法校正后OR 3.98。
  • 肺动脉导管使用与脓毒症风险增加相关:OR 1.83(95%CI 1.42-2.35,I²=61%)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入观察性研究。
  • 局限:异质性显著(I²>90%);发表偏倚(Egger P=0.0057)。

对床旁实践的改变

  • 作者认为,研究结果支持将系统性肺动脉导管使用作为心源性休克的治疗促进手段,并应指导方案制定和未来随机临床试验设计。
  • 肺动脉导管使用与机械循环支持启动增加相关,同时与脓毒症风险增加相关,临床决策时需权衡。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The role of pulmonary artery catheterization (PAC) in cardiogenic shock (CS) remains debated: prior intensive care unit trials showed no benefit, but contemporary observational registries suggest improved outcomes. However, the overall evidence remains fragmented, with inconsistent phenotypic and outcome reporting. Our objective was to assess the association between PAC use and clinical outcomes in CS.

METHODS: We systematically searched MEDLINE, Cochrane, and Scopus (2015-2025) for observational and registry studies in adult CS. Outcomes included in-hospital/30-day mortality, mechanical circulatory support (MCS), and sepsis. Pooled odds ratios (OR) and hazard ratios were estimated using random-effects models. Subgroup, meta-regression, and trial sequential analysis were performed.

RESULTS: Fourteen observational studies (n = 789,553; 271,305 deaths) were included. Overall mortality averaged 34%. PAC use was associated with lower mortality (OR 0.70, 95% confidence interval [CI] 0.63-0.78; P < 0.001) with consistent benefit across CS phenotypes, although substantial heterogeneity was present (I² > 90%). Time-to-event analyses (7 studies, n = 5,142) confirmed a 32% relative hazard ratio (0.68, 95% CI 0.60-0.77; I² = 34%). PAC use was also linked to higher MCS initiation (OR 2.76, 95% CI 1.82-4.20; P < 0.001), with evidence of publication bias (Egger P = 0.0057) and an adjusted OR 3.98 after trim-and-fill. In addition, PAC was associated with increased sepsis risk (OR 1.83, 95% CI 1.42-2.35; I² = 61%).

CONCLUSIONS: PAC use was consistently associated with improved survival across CS, and higher MCS use was associated with increased sepsis risk. Our findings support systematic PAC use as a therapeutic enabler in CS and should inform protocols and future randomized clinical trials design.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Ortega-Hernández JA, Chacon-Lozsan FJ, Baldetti L, et al. Pulmonary Artery Catheter Monitoring in Cardiogenic Shock: A Systematic Review and Meta-Analysis. Shock. 2026. PMID: 41894663. doi:10.1097/SHK.0000000000002784

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。